A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

NCT05226507 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Ovarian Cancer
Ovarian Clear Cell Carcinoma
Ovarian Clear Cell Tumor
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Endometrioid Tumor
ARID1A Gene Mutation

Interventions

DRUG: NXP800

Sponsor

Nuvectis Pharma, Inc.

Collaborators

[object Object]
[object Object]